BOND: Benchmarking based on heterogeneous biOmedical Network and Deep learning novel drug-target associations
BOND: Benchmarking based on heterogeneous biOmedical Network and Deep learning novel drug-target associations
批准号:
10227201
负责人:
NANSU ZONG
金额:
$0.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-01 至 2021-08-31
关键词:
AddressAlgorithmsAreaBase RatiosBenchmarkingBig DataClinicComputational BiologyComputer AssistedData SetData SourcesDatabasesDevelopmentDimensionsDiseaseDrug EvaluationDrug TargetingElectronic Health RecordEmploymentEvaluationFoundationsGenerationsGeneticGoalsGraphInvestigationLearningLearning ModuleLinkMachine LearningMentorsMethodologyMethodsMiningModelingMolecularNetwork-basedPharmaceutical PreparationsPharmacologyPhasePlayPositioning AttributeResearchResearch PersonnelRoleSamplingSilverSourceStandardizationStructureSystems BiologyTechnologyTestingTrainingUrsidae FamilyValidationbasebiomedical informaticscancer genomicscomputer based Semantic Analysiscostdata integrationdata managementdata toolsdeep learningdeep neural networkdesigndrug developmentdrug repurposingflexibilityheterogenous dataimprovedin silicoknowledge baselarge scale datalearning algorithmlearning strategymachine learning algorithmnew therapeutic targetnovelprecision medicinepredictive modelingpredictive testprogramsrepositoryscreeningskillstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
The applicant’s goals are to develop the necessary skills to become an independent translational biomedical
informatics researcher in the area of computational drug repurposing. Exploring novel drug-target interactions
(DTI) plays a crucial role in drug development. In order to lower the overall costs and uncover more potential
screening targets, computational (in silico) methods have become popular and are commonly applied to
poly-pharmacology and drug repurposing. Although machine learning-based strategies have been studied for
years, there is no standardized benchmark that provides large-scale training datasets as well as diverse
evaluation tasks to test different methods. Furthermore, the existing methods suffer from remarkable limitations,
where 1) results are often biased due to a lack of negative samples, 2) novel drug-target associations with new
(or isolated) drugs/targets cannot be explored,
and 3) the comprehensive topological structure cannot be
captured by feature learning methods
. Therefore, in the era of big data, the applicant proposes a study to tackle
the challenges by achieving two aims.
• Aim 1 (K99 Phase): Develop a large scale benchmark for evaluating drug-target prediction based on the
generation of a multipartite network from heterogeneous biomedical datasets.
• Aim 2 (R00 Phase): Adapt a deep learning model to build an accurate predictive model based on a novel
feature learning algorithm that mines the multi-dimensional biomedical network (multipartite network).
In the mentored phase, the applicant will integrate heterogeneous biomedical datasets and build a benchmark
for evaluation of the drug-target prediction based on well-designed strategies. The applicant will receive training
in standardization tools for data integration, tools, and skills for data management, evaluation methods for
drug-target predictions, and state-of-the-art machine learning/deep learning methods in computer-aided
pharmacology. Complementary didactic, intellectual, and professional training will help prepare the applicant for
the R00 phase where he will develop a deep learning-based predictive model and multi-dimensional graph
embedding methods for feature learning. Together, these novel studies will advance the current computational
drug repurposing by providing 1) comprehensive benchmarking for testing and evaluation, and 2) a scalable
and accurate predictive model based on a biomedical multi-partite network.
The applicant will be mentored by
senior, established investigators with substantial expertise in Semantic Web, computational biology, cancer
genomics, drug development, and machine learning/deep learning.
Importantly, this project will provide a
foundation for the applicant to establish independent research programs in
1) computational drug repurposing in
real cases, 2) investigation of the diverse hidden associations in system biology (e.g., associations between
drugs, genetics, and diseases), and 3) precision medicine aimed applications leveraging biomedical
knowledgebases and electronic health records.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.2196/38584
发表时间:
2022-07-06
期刊:
JOURNAL OF MEDICAL INTERNET RESEARCH
影响因子:
7.4
作者:
[Jiang, Chao, Ngo, Victoria, Chapman, Richard, Yu, Yue, Liu, Hongfang, Jiang, Guoqian, Zong, Nansu]
通讯作者:
Zong, Nansu
DOI:
10.1038/s41746-022-00617-6
发表时间:
2022-06-14
期刊:
NPJ digital medicine
影响因子:
15.2
作者:
[]
通讯作者:
DOI:
10.2196/23586
发表时间:
2021-05-25
期刊:
JMIR medical informatics
影响因子:
3.2
作者:
[Zong N, Ngo V, Stone DJ, Wen A, Zhao Y, Yu Y, Liu S, Huang M, Wang C, Jiang G]
通讯作者:
Jiang G
DOI:
10.1093/bib/bbac199
发表时间:
2022-07-18
期刊:
Briefings in bioinformatics
影响因子:
9.5
作者:
[]
通讯作者:
BOND: Benchmarking based on heterogeneous biOmedical Network and Deep learning novel drug-target associations
-
批准号:10443949
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2020
-
负责人:NANSU ZONG
-
依托单位:
BOND: Benchmarking based on heterogeneous biOmedical Network and Deep learning novel drug-target associations
-
批准号:10054989
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2020
-
负责人:NANSU ZONG
-
依托单位:
海外基金